Search

Displaying results 861 - 870 of 7674 in total
  1. Drug

    Thonzylamine

    go.drugbank.com/drugs/DB11235
    Approved

    Thonzylamine is an antihistamine and anticholinergic drug.

    Mixtures: Poly-Hist DM
  2. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942] … Due to its very low water solubility, butamben is considered to be suitable only for topical anesthesia.

  3. Drug

    Magnesium acetate tetrahydrate

    go.drugbank.com/drugs/DB09409
    ApprovedWithdrawn

    Magnesium acetate tetrahydrate can be used as an electrolyte supplementation or a reagent in molecular biology experiments. … Magnesium is an essential element and second most abundant cation in the body that plays a key role in maintaining normal cellular function such as production of ATP and efficient enzyme activity.

    Mixtures: ELETTROLITICA BILANCIATA DI MANTENIMENTO CON GLUCOSIO S.A.L.F., ELETTROLITICA BILANCIATA DI MANTENIMENTO CON GLUCOSIO BIOINDUSTRIA L.I.M.
  4. Drug

    Clonidine

    go.drugbank.com/drugs/DB00575
    ApprovedInvestigational

    [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237] … Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.

    Products: Nu-clonidine Tab 0.2mg, Nu-clonidine Tab 0.1mg
  5. Drug

    Rifaximin

    go.drugbank.com/drugs/DB01220
    ApprovedInvestigational

    It is marketed under the brand name Xifaxan by Salix Pharmaceuticals. … indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D)

    Products: RIFAXIMINA DOC GENERICI, RIFAXIMINA MYLAN GENERICS
  6. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [L41404] Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers

  7. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.

  8. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. … [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]

  9. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

    Mixtures: Polytussin DM, WesTussin DM
  10. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020,[L13236] remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22 … [L39640] Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.[L22619]